UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation: follow-up to age 4 years

doi:10.1016/S0140-6736(00)04310-5

The Lancet

Volume 357, Issue 9262, 7 April 2001, Pages 1094-1096

https://doi.org/10.1016/S0140-6736(00)04310-5 Get rights and content

Summary

Extracorporeal membrane oxygenation (ECMO) is a supportive intensive-care technique used for babies with acute respiratory failure. We examined morbidity at age 4 years in surviving children recruited to the UK Collaborative ECMO Trial, and provide long-term data on ECMO support compared with contemporary conventional care. The neonatal ECMO policy resulted in improved survival and a favourable outcome. We therefore advocate the safety and efficacy of this intervention.

References (5)

UK Collaborative ECMO Trial Group
UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation
Lancet
(1996)
UK Collaborative ECMO Group
The Collaborative ECMO trial: follow-up to 1 year of age
Pediatrice
(1998)

There are more references available in the full text version of this article.

Cited by (175)

Comorbidities and Late Outcomes in Neonatal Pulmonary Hypertension
2024, Clinics in Perinatology
Pediatric ECLS Neurologic Management and Outcomes
2023, Seminars in Pediatric Surgery
Neurologic complications associated with extracorporeal life support (ECLS), including seizures, ischemia/infarction, and intracranial hemorrhage significantly increase morbidity and mortality in pediatric and neonatal patients. Prompt recognition of adverse neurologic events may provide a window to intervene with neuroprotective measures. Many neuromonitoring modalities are available with varying benefits and limitations. Several pre-ECLS and ECLS-related factors have been associated with an increased risk for neurologic complications. These may be patient- or circuit-related and include modifiable and non-modifiable factors. ECLS survivors are at risk for long-term neurological sequelae affecting neurodevelopmental outcomes. Possible long-term outcomes range from normal development to severe impairment. Patients should undergo a neurological evaluation prior to discharge, and neurodevelopmental assessments should be included in each patient's structured, multidisciplinary follow-up.
Safe pediatric and neonatal ECLS management requires a thorough understanding of neurological complications, neuromonitoring techniques and limitations, considerations to minimize risk, and an awareness of possible long-term ramifications. With a focus on ECLS for respiratory failure, this manuscript provides a review of these topics and summarizes best practice guidelines from international organizations and expert consensus.
Persistent Pulmonary Hypertension
2023, Avery's Diseases of the Newborn
Persistent pulmonary hypertension of the newborn (PPHN) represents the failure of the pulmonary circulation to undergo the normal fall in pulmonary vascular resistance (PVR) at birth in order to accommodate the marked rise in pulmonary blood flow that enables the successful transition to postnatal life. PPHN is characterized by severe hypoxemia secondary to sustained elevation of PVR resulting in right-to-left extrapulmonary shunting of deoxygenated blood. PPHN is associated with diverse cardiopulmonary disorders and high early mortality rate for infants with severe disease, especially in the setting of genetic causes of developmental lung disease. Surviving infants with PPHN have an increased risk of long-term comorbidities. PPHN physiology can be categorized by (1) maladaptation: pulmonary vessels have normal structure and number but have abnormal vasoreactivity; (2) excessive muscularization: increased smooth muscle cell thickness and increased distal extension of muscle to vessels that are usually not muscularized; and (3) underdevelopment: lung hypoplasia associated with decreased pulmonary artery number. Treatment involves adequate lung recruitment, optimization of cardiac output and left ventricular function, and pulmonary vasodilators such as inhaled nitric oxide. Infants who fail to respond to conventional therapy should be evaluated for lethal genetic lung disorders, including alveolar capillary dysplasia (ACD), TBX4, TTF-1, ABCA3, surfactant protein diseases, and others.
Neonatal ECMO survivors: The late emergence of hidden morbidities – An unmet need for long-term follow-up
2022, Seminars in Fetal and Neonatal Medicine
Long term outcome of babies with pulmonary hypertension
2022, Seminars in Fetal and Neonatal Medicine
Neonatal pulmonary hypertension (PH) is associated with many severe congenital abnormalities (congenital diaphragmatic hernia) or acquired cardiorespiratory diseases such as pneumonia, meconium aspiration and bronchopulmonary dysplasia (BPD). If no cause is found it may be labelled idiopathic persistent pulmonary hypertension of the newborn. Although PH may result in life threatening hypoxia and circulatory failure, in the majority of cases, it resolves in the neonatal period following treatment of the underlying cause. However, in some cases, neonatal PH progresses into infancy and childhood where symptoms include failure to thrive and eventually right heart failure or death if left untreated. This chronic condition is termed pulmonary vascular hypertensive disease (PHVD). Although classification and diagnostic criteria have only recently been proposed for pediatric PHVD, little is known about the pathophysiology of chronic neonatal PH, or why pulmonary vascular resistance may remain elevated well beyond infancy. This review explores the many factors involved in chronic PH and what implications this may have on long term outcome when the disease progresses beyond the neonatal period.
Extracorporeal membrane oxygenation
2022, Goldsmith's Assisted Ventilation of the Neonate: An Evidence-Based Approach to Newborn Respiratory Care, Seventh Edition

View all citing articles on Scopus

See The Lancet website www.thelancet.com for a list of contributing members.

Further information available on at www.thelancet.com

View full text

Research LettersUK collaborative randomised trial of neonatal extracorporeal membrane oxygenation: follow-up to age 4 years

Summary

UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation

Lancet

The Collaborative ECMO trial: follow-up to 1 year of age

Pediatrice

Research Letters
UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation: follow-up to age 4 years